Lonza Strengthens pharma, biotech and nutrition offerings26 Feb 2019
With the new structure, Lonza is positioned to leverage its innovation programs and technology platforms to create new solutions at the food-pharma convergence and in microbial control.
Lonza has announced the internal alignment of its business structure to accelerate growth along the Healthcare Continuum and strengthen the Microbial Control business. Stefan Stoffel has been appointed to a new role on the Executive Committee as COO, Lonza Pharma Biotech & Nutrition (LPBN), responsible for operations, from 1 March.
Incoming Group CEO Marc Funk commented: “Our new structure will nurture synergies and increase operational efficiency, which will create customer benefits. More importantly, it will enable Lonza to develop a more compelling offer across pharma, biotech and nutrition and to extend our competitive advantage in the market. Stefan is a well-regarded, long-established and strong leader in the Lonza business. His oversight of LPBN segment operations will help us to galvanize our offering and capitalize on future opportunities.”
The company will maintain two segments spanning the Healthcare Continuum – one dedicated to Lonza Specialty Ingredients (LSI) that will retain Consumer & Resources Protection and Consumer Product Ingredients and a second to Lonza Pharma Biotech & Nutrition (LPBN), combining Pharma & Biotech and Consumer Health & Nutrition.
In his newly created position, Stefan Stoffel will cover Operations, Quality, Engineering and Strategic Growth Initiatives across the LPBN segment. Stefan has been with Lonza since 1991 and has been instrumental in setting up a number of successful strategic projects, including IbexTM. Stefan will join Marc Funk (incoming CEO), Sven Abend (COO LSI) and Rodolfo Savitzky (CFO) on the Executive Committee. The commercial functions of the new LPBN segment will be driven by Marc Funk for the time being.
The alignment will enable both segments to focus on operational excellence, including an integrated global asset strategy that enables a more-cohesive supply chain and asset utilization. For the LSI segment, synergies across R&D and commercial functions will open up new market opportunities for the Microbial Control business and enable faster innovation. In the LPBN segment, translation of technology and know-how from pharma to nutrition, including regulatory and scientific expertise, will strengthen Lonza’s offering.
With this new structure, Lonza is positioned to leverage its innovation programs and technology platforms to create new solutions at the food-pharma convergence and in microbial control. Along the full spectrum, from advanced personalized medicines to functional foods, nutrition and a healthy environment, Lonza will continue to focus on driving a differentiated offering to support healthy living and to fully serve the needs of patients and consumers.
All future financial reporting will be based on the two new segments Lonza Pharma Biotech & Nutrition (LPBN) and Lonza Specialty Ingredients (LSI).
Improving gut health with human milk oligosaccharides
17 May 2019
2’-FL a very promising agent for digestive health across various age groups beyond infancy.Read more
Expert forecasts huge growth in Middle East manufacturing
16 May 2019
UAE consumers and insurance companies are willing to pay for highest quality drug products.Read more
Colorcon's breakthrough for direct compression
15 May 2019
New starch-based excipient plays an important role in enhancing the stability of moisture-sensitive APIs.Read more
Legacy plans for lyophilisation boom
14 May 2019
The increase in biologics is driving the growth in demand for lyophilization in vials.Read more
Lessons learned from early EU FMD adopters
13 May 2019
Data exchange, investment costs, resources and hardware identified as some of the biggest challenges.Read more
Catalent achieves global ISO accreditation
12 May 2019
Company is one of the first CDMOs to receive award.Read more
Vibalogics increases capacity with a new 200-L line for virus manufacturing
9 May 2019
Company has also invested in an Äkta-ready chromatography system for downstream processing and liquid handling equipment to deal with increased volumes.Read more
New SIMCA 16 software for multivariate data analytics
8 May 2019
Makes model data easier to interpret for better process control.Read more
Recipharm launches its end-to-end inhalation offering
7 May 2019
Offers a seamless outsourcing service for inhalation products, including MDIs, DPIs and nasal sprays.Read more
Accessible online courses designed to improve tablet compression tooling
7 May 2019
I Holland launches online training for all levels of pharmaceutical and nutraceutical professionals.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation